(Reuters Health) – Diabetics with irregular sleep schedules that diverge from their internal body clocks may be at increased risk for dangerously high blood sugar, a small study suggests.
Much as jetting across time zones can force a person to wake-up, eat and work at times that conflict with their body’s idea of what time it is, so-called social jet lag happens when social pressures like work or school cause people to be active at times that conflict with their natural internal clock. In the study, researchers measured social jet lag by tracking the degree to which people followed one sleep schedule on work days and another on days off.
Researchers at the Icahn School of Medicine, Mount Sinai, New York have reported a pilot clinical trial with a “nanoparticle-based photothermal cancer therapy” for prostate cancers. Their work with this targeted therapy is published in a study titled, “Gold nanoshell-localized photothermal ablation of prostate tumors in a clinical pilot device study,” in the latest issue of the journal Proceedings of National Academy of Science.
Art Rastinehad, DO, Associated Professor of Urology and Radiology at the Icahn School of Medicine at Mount Sinai, is leading the first clinical trial of gold nanoparticles to treat prostate cancer.
FILE PHOTO: A logo of Sanofi is pictured during the company’s shareholder meeting in Paris, France, April 30, 2019. REUTERS/Benoit Tessier/File Photo
(Reuters) – A U.S. judge on Wednesday largely set aside a jury verdict that Amgen Inc patents on its cholesterol drug Repatha were valid, handing a victory to Regeneron Pharmaceuticals Inc and Sanofi SA (SASY.PA), which make a rival drug.
The ruling from a Wilmington, Delaware, judge was the latest reversal of fortune in a long-running lawsuit in which Amgen is seeking to stop Sanofi and Regeneron from selling their Praluent, a medicine that competes with Repatha and is intended to lower bad LDL cholesterol by blocking a protein known as PCSK9.
FILE PHOTO: The headquarters of the U.S. Food and Drug Administration (FDA) is shown in Silver Spring, Maryland, November 4, 2009. REUTERS/Jason Reed/File Photo
(Reuters) – The U.S. Food and Drug Administration said on Wednesday it had identified 63 cases of worsening liver function in certain patients taking hepatitis C medicines made by drugmakers Merck & Co Inc, Gilead Sciences and AbbVie Inc.
The agency said that while the treatments are safe and effective, it had received reports of rare but serious instances of worsening liver function or failure when they were taken by patients with advanced liver disease. (reut.rs/2Zu2xoN)
MONDAY, Aug. 26, 2019 (HealthDay News) — Seniors, here’s a recipe for preventing dementia: eat well, exercise and don’t smoke.
The only catch, according to a new study? If you carry genes that leave you vulnerable to the memory-robbing disease, lifestyle might not be enough.
In the study, researchers found that of over 6,300 adults aged 55 and older, those with healthy habits had a lower risk of being diagnosed with dementia over the next 15 years. That was true, at least, for people at low or intermediate risk of dementia because of their genes.
Biocompatible gold nanoparticles designed to convert near-infrared light to heat have been shown to safely and effectively ablate low- to intermediate-grade tumors within the prostate, according to a study conducted at the Icahn School of Medicine and published in the journal Proceedings of the National Academy of Sciences. This treatment could offer patients a targeted therapy option that would preserve critical structures within the prostate, thus avoiding side effects associated with whole-gland treatment such as prostatectomies.
(Reuters) – OxyContin maker Purdue Pharma and its owners, the Sackler family, is in discussion to settle more than 2,000 lawsuits against the company for $10 billion to $12 billion, two people familiar with the matter said on Tuesday.
FILE PHOTO: Bottles of prescription painkiller OxyContin pills, made by Purdue Pharma sit on a counter at a local pharmacy in Provo, Utah, U.S., April 25, 2017. REUTERS/George Frey/File Photo
Purdue is among several drugmakers and distributors that are facing lawsuits, seeking to hold them responsible for fueling the U.S. opioid addiction crisis, which has claimed thousands of lives.
NORMAN, Okla./BOSTON (Reuters) – An Oklahoma judge on Monday ordered Johnson & Johnson (JNJ.N) to pay $572.1 million to the state for its part in fueling an opioid epidemic by deceptively marketing addictive painkillers, a sum that was substantially less than investors had expected, driving up J&J’s shares.
The state’s attorney general had filed the lawsuit, seeking $17 billion to address the impact of the drug crisis on Oklahoma. It had been considered a bellwether for other litigation nationwide over the opioid epidemic.
WEDNESDAY, Aug. 21, 2019 (HealthDay News) — Could a pacemaker for the brain improve the memories of people with dementia or Alzheimer’s disease?
New research suggests it might be possible one day: Electrical stimulation directed at key memory regions of the brain created intense flashbacks in some Alzheimer’s patients, including sensations of emotions, smells, taste and temperature.
In one case, a patient suddenly recalled “an entire experience of being inebriated while drinking a margarita at a resort in Aruba,” researchers said. In another, a man had a vivid flashback of feeling very full after eating sardines on his front porch two decades previously.